WO2000033887A3 - Methods and formulations for reducing circulating antibodies - Google Patents

Methods and formulations for reducing circulating antibodies Download PDF

Info

Publication number
WO2000033887A3
WO2000033887A3 PCT/US1999/029336 US9929336W WO0033887A3 WO 2000033887 A3 WO2000033887 A3 WO 2000033887A3 US 9929336 W US9929336 W US 9929336W WO 0033887 A3 WO0033887 A3 WO 0033887A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
reducing circulating
formulations
antibodies
circulating antibodies
Prior art date
Application number
PCT/US1999/029336
Other languages
French (fr)
Other versions
WO2000033887A2 (en
Inventor
Richard M Jack
David S Jones
Lin Yu
Steven B Engle
Original Assignee
Jolla Pharma
Richard M Jack
David S Jones
Lin Yu
Steven B Engle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Pharma, Richard M Jack, David S Jones, Lin Yu, Steven B Engle filed Critical Jolla Pharma
Priority to JP2000586377A priority Critical patent/JP2002531531A/en
Priority to AU21735/00A priority patent/AU2173500A/en
Priority to EP99966115A priority patent/EP1135167A2/en
Priority to CA002353620A priority patent/CA2353620A1/en
Publication of WO2000033887A2 publication Critical patent/WO2000033887A2/en
Publication of WO2000033887A3 publication Critical patent/WO2000033887A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

The invention provides methods for reducing circulating levels of antibodies, particularly disease-associated antibodies. The methods entail administering effective amounts of epitope-presenting carriers to an individual. In other embodiments, ex vivo methods for reducing circulating levels of antibodies are provided which employ epitope-presenting carriers.
PCT/US1999/029336 1998-12-08 1999-12-09 Methods and formulations for reducing circulating antibodies WO2000033887A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000586377A JP2002531531A (en) 1998-12-09 1999-12-09 Methods and formulations for reducing circulating antibodies
AU21735/00A AU2173500A (en) 1998-12-09 1999-12-09 Methods and formulations for reducing circulating antibodies
EP99966115A EP1135167A2 (en) 1998-12-09 1999-12-09 Methods and formulations for reducing circulating antibodies
CA002353620A CA2353620A1 (en) 1998-12-09 1999-12-09 Methods and formulations for reducing circulating antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45787598A 1998-12-08 1998-12-08
US11163998P 1998-12-09 1998-12-09
US45787599A 1999-12-08 1999-12-08
US09/457,875 1999-12-08
US60/111,639 1999-12-08

Publications (2)

Publication Number Publication Date
WO2000033887A2 WO2000033887A2 (en) 2000-06-15
WO2000033887A3 true WO2000033887A3 (en) 2000-08-17

Family

ID=26809097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029336 WO2000033887A2 (en) 1998-12-08 1999-12-09 Methods and formulations for reducing circulating antibodies

Country Status (5)

Country Link
EP (1) EP1135167A2 (en)
JP (1) JP2002531531A (en)
AU (1) AU2173500A (en)
CA (1) CA2353620A1 (en)
WO (1) WO2000033887A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005236A (en) 1999-11-28 2004-03-19 Jolla Pharma Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof.
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
ES2865148T3 (en) 2014-03-13 2021-10-15 Univ Basel Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
CN108026134A (en) 2015-09-16 2018-05-11 巴塞尔大学 With reference to the carbohydrate ligand of anti-glycosphingolipid glycoprotein epitope antibodies
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
BR112023005285A2 (en) 2020-09-23 2023-04-25 Ablevia Biotech Gmbh COMPOUND TO INCREASE THE EFFECTIVENESS OF VIRAL VECTORS
IL301332A (en) 2020-09-23 2023-05-01 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
TW202228784A (en) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 Compound for the sequestration of undesirale anti-peg antibodies in a patient
JP2023542388A (en) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー Compounds for increasing the effectiveness of factor VIII replacement therapy
WO2022063879A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
CN116710143A (en) 2020-09-24 2023-09-05 艾柏力维亚生技有限公司 Compounds for preventing or treating myasthenia gravis
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003735A1 (en) * 1991-08-23 1993-03-04 Alberta Research Council Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
WO1995007073A1 (en) * 1993-09-08 1995-03-16 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
WO1998047915A1 (en) * 1997-04-18 1998-10-29 Novartis Ag Neoglycoproteins
WO1999052561A1 (en) * 1998-04-15 1999-10-21 Baxter International Inc. Inhibition of xenoreactive antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
WO1993003735A1 (en) * 1991-08-23 1993-03-04 Alberta Research Council Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
WO1995007073A1 (en) * 1993-09-08 1995-03-16 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
WO1998047915A1 (en) * 1997-04-18 1998-10-29 Novartis Ag Neoglycoproteins
WO1999052561A1 (en) * 1998-04-15 1999-10-21 Baxter International Inc. Inhibition of xenoreactive antibodies

Also Published As

Publication number Publication date
WO2000033887A2 (en) 2000-06-15
CA2353620A1 (en) 2000-06-15
EP1135167A2 (en) 2001-09-26
JP2002531531A (en) 2002-09-24
AU2173500A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
WO2000033887A3 (en) Methods and formulations for reducing circulating antibodies
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
AU2002327180A1 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
HK1044543A1 (en) Beta-secretase enzyme compositions and methods.
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
WO2003053997A3 (en) Methods of increasing endogenous erythropoietin (epo)
DE69907240T2 (en) FIXED PHYTASE COMPOSITIONS
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
EP1100522A4 (en) Pulmonary delivery of active agents
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
WO1998046257A8 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
BG101892A (en) Sugar-modified cytostatics
WO2001034647A3 (en) Animal collagens and gelatins
MXPA02003232A (en) Compositions and methods for altering gene expression.
ZA985026B (en) Method for enhancing the activity of an enzyme.
ATE242630T1 (en) LOADED BACTERIAL GHOSTS AS CARRIER AND TARGET VEHICLES
WO2004008286A3 (en) Arrangements and methods for treating a subject
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU3828699A (en) Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitorsof the activation of the nuclear transcription factors nf-Kappa
IL148514A0 (en) Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
IL148193A0 (en) Hard candy with improved storage stability
GB9923858D0 (en) Antimicrobial compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2353620

Country of ref document: CA

Ref country code: CA

Ref document number: 2353620

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 586377

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 21735/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999966115

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999966115

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999966115

Country of ref document: EP